The agreement with Quantum Pharma is an important step towards the commercial launch of MED2002, a topical treatment of erectile dysfunction, in the UK as an unlicensed medicine (‘Special’). MED2002 can be used to treat the significant proportion (c. 7.5%) of erectile dysfunction patients who cannot be prescribed sildenafil (Viagra®) due to contraindications. Quantum Pharma has a leading position in the UK Specials market and we view the company as an ideal partner for Futura Medical. We continu ....
14 Oct 2015
Out-licensing deal for MED2002 with Quantum Pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Out-licensing deal for MED2002 with Quantum Pharma
Futura Medical plc (FUM:LON) | 36.0 0.2 1.5% | Mkt Cap: 108.4m
- Published:
14 Oct 2015 -
Author:
Dr Jens Lindqvist -
Pages:
3
The agreement with Quantum Pharma is an important step towards the commercial launch of MED2002, a topical treatment of erectile dysfunction, in the UK as an unlicensed medicine (‘Special’). MED2002 can be used to treat the significant proportion (c. 7.5%) of erectile dysfunction patients who cannot be prescribed sildenafil (Viagra®) due to contraindications. Quantum Pharma has a leading position in the UK Specials market and we view the company as an ideal partner for Futura Medical. We continu ....